CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States
CAR-T therapy recipients experienced longer delays before needing additional treatment, though only a small fraction of eligible patients currently access it.
This retrospective claims-based cohort study examined CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States. Only 20% of eligible patients were referred and 15% received CAR-T, while recipients had longer time to next treatment or death than nonrecipients.
What the study was
- Study design
- Retrospective claims-based cohort study
- Population
- US adults with relapsed or refractory large B-cell lymphoma after at least two prior treatment lines
- Sample size
- 8,959 patients
- Category
- Public Health
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
Retrospective claims-based cohort study; Only 20% of eligible patients were referred and 15% received CAR-T, while recipients had longer time to next treatment or death than nonrecipients. Score kept conservative because only the PubMed abstract and metadata were reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.